CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 32 enrolled
Drug / intervention
Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg) +11 moredrug
Likely dose
Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02451748
NCT02451748Phase 4Completed
CompareCT.gov

IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA

University of Illinois at Chicago·interventional·Posted May 22, 2015·Updated Jul 10, 2024

In Brief

A Phase 4 clinical trial evaluating Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), and 10 other interventions for Rheumatoid Arthritis. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The purpose of the study is to better understand the factors present in the cells of inflamed joints of patients with arthritis that may cause rheumatoid arthritis. Knowledge gained from this study may lead to new and better therapies for arthritis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
CollaboratorsUCB Pharma

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 22, 2015
Enrollment StartAug 1, 2015
Primary CompletionSep 1, 2017
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.1 years ago

Interventions

Lab Workother

Lab work to measure IL-7 and IL-7R

Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)drug

Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg. Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection.

Certolizumab pegol (CDP870, tradename Cimzia)drug

rtolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg. Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection.

Hydroxychloroquinedrug

some patients are on 400mg/day of hydroxychloroquine.

Sulfasalazinedrug

some patients are on 300 mg/day and some patients are on 1000 mg/day dose of sulfasalazine

Medroldrug

some patients are on 8mg/day of medrol

Prednisonedrug

some patients are on 10mg /day, some patients are on 20 mg/day, some patients are on 2.5 mg/day, some patients are on 30 mg/day, and some patients are on 5 mg/day of prednisone

Triamcinolonedrug

some patients are on Triamcinolone 40-80mg IM monthly (received 40mg dose 1 week before blood draw, off enbrel 50mg weekly and SSZ 1000mg bid for \~ 3 months) some patients are on Triamcinolone 40mg IM monthly

Naproxendrug

some patients are on 1000 mg/day of naproxen

Leflunomidedrug

some patients are on 20mg/day of leflunomide

Methotrexatedrug

some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate

humiradrug

some patients are on Humira 40mg q2weeks